ArticleMolecular systems biology2019
Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy.
Open access · goldAbstract read
In one paragraph
Article in Molecular systems biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 33 citations in OpenAlex.
- Transcriptome-Based Synthetic Lethality Predictions to Improve Targeted Therapy/Immunotherapy Treatment Prioritization in Nonmetastatic Breast Cancer: BC-SELECT.Cancer research communications · 2026Article
- GiGCN: a network-based framework for uncovering synthetic lethal and viable genetic interactions.Briefings in bioinformatics · 2026Article
- Immune checkpoint B7x promotes immune evasion and resistance to PD-1/PD-L1 blockade in bladder cancer.Genes & diseases · 2026Article
- Optimizing transcriptome-based synthetic lethality predictions to improve targeted therapy / immunotherapy treatment prioritization in non-metastatic breast cancer: BC-SELECT.bioRxiv : the preprint server for biology · 2026Article
- DISCERN: inferring drug sensitivity from single-cell transcriptomes using cell-type-specific genetic interaction networks.Genome medicine · 2026Article
- Genome-wide investigation of synthetic rescue interactions in Alzheimer's disease implicates glial lipid and sterol metabolism.Alzheimer's research & therapy · 2026Article
- Tripleknock: predicting lethal effect of three-gene knockout in bacteria by deep learning.Scientific reports · 2026Article
- Charting cell-type-specific positive genetic interaction at single-cell resolution for lung adenocarcinoma.NPJ precision oncology · 2026Article
- Epigenetic synthetic lethality as a cancer therapeutic strategy: synergy of experimental and computational approaches.Epigenomics · 2025Review
- Identification of Anticancer Targets in Ovarian Cancer Using Genomic Drug Sensitivity Data.International journal of molecular sciences · 2025Article
- Chromosome 7 Gain Compensates for Chromosome 10 Loss in Glioma.Cancer research · 2024Article
- MAGICAL: A multi-class classifier to predict synthetic lethal and viable interactions using protein-protein interaction network.PLoS computational biology · 2024Article
- Synthetic viability induces resistance to immune checkpoint inhibitors in cancer cells.British journal of cancer · 2023Article
- A landscape of response to drug combinations in non-small cell lung cancer.Nature communications · 2023Article
- Genomic and transcriptomic analyses identify a prognostic gene signature and predict response to therapy in pleural and peritoneal mesothelioma.Cell reports. Medicine · 2023Article
- Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome.Med (New York, N.Y.) · 2023Article
- Big data in basic and translational cancer research.Nature reviews. Cancer · 2022Review
- Potential Biomarkers of Skin Melanoma Resistance to Targeted Therapy-Present State and Perspectives.Cancers · 2022Review
- Harnessing Synthetic Lethal Interactions for Personalized Medicine.Journal of personalized medicine · 2022Review
- Potential genetic biomarkers predict adverse pregnancy outcome during early and mid-pregnancy in women with systemic lupus erythematosus.Frontiers in endocrinology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors at 9 institutions in 2 countries.
Avinash Das SahuDepartment of Biostatistics and Computational Biology, Harvard School of Public Health, Boston, MA, USA asahu@jimmy.harvard.edu eyruppin@gmail.com.ORCID 0000-0002-2193-6276
Joo S LeeUniversity of Maryland Institute of Advanced Computer Science (UMIACS), University of Maryland, College Park, MD, USA.ORCID 0000-0001-8564-0848
Zhiyong WangDepartment of Pharmacology & Moores Cancer Center, University of California, San Diego La Jolla, CA, USA.
Gao ZhangMolecular and Cellular Oncogenesis Program and Melanoma Research Center, The Wistar Institute, Philadelphia, PA, USA.
Ramiro Iglesias-BartolomeNational Cancer Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-0792-1254
Tian TianNew Jersey Institute of Technology, Newark, NJ, USA.ORCID 0000-0001-6147-1082
Zhi WeiNew Jersey Institute of Technology, Newark, NJ, USA.
Benchun MiaoDepartment of Medicine and Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Nishanth Ulhas NairUniversity of Maryland Institute of Advanced Computer Science (UMIACS), University of Maryland, College Park, MD, USA.
Olga PonomarovaUniversity of Massachusetts Medical School, Worcester, MA, USA.
Adam A FriedmanDepartment of Medicine and Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Arnaud AmzallagDepartment of Medicine and Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Tabea MollDepartment of Medicine and Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Gyulnara KasumovaDepartment of Medicine and Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Patricia GreningerDepartment of Medicine and Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Regina K EganDepartment of Medicine and Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Leah J DamonDepartment of Medicine and Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Dennie T FrederickDepartment of Medicine and Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Livnat Jerby-ArnonSchools of Computer Science & Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Allon WagnerDepartment of Electrical Engineering and Computer Science, the Center for Computational Biology, University of California, Berkeley, CA, USA.
Kuoyuan ChengUniversity of Maryland Institute of Advanced Computer Science (UMIACS), University of Maryland, College Park, MD, USA.
Seung Gu ParkDepartment of Biostatistics and Computational Biology, Harvard School of Public Health, Boston, MA, USA.
Welles RobinsonUniversity of Maryland Institute of Advanced Computer Science (UMIACS), University of Maryland, College Park, MD, USA.
Kevin GardnerCancer Data Science Lab, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Genevieve BolandDepartment of Medicine and Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Sridhar HannenhalliUniversity of Maryland Institute of Advanced Computer Science (UMIACS), University of Maryland, College Park, MD, USA.
Meenhard HerlynMolecular and Cellular Oncogenesis Program and Melanoma Research Center, The Wistar Institute, Philadelphia, PA, USA.
Cyril BenesDepartment of Medicine and Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Keith FlahertyDepartment of Medicine and Harvard Medical School, Massachusetts General Hospital Cancer Center, Boston, MA, USA.
Ji LuoNational Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
J Silvio GutkindDepartment of Pharmacology & Moores Cancer Center, University of California, San Diego La Jolla, CA, USA.
Eytan RuppinUniversity of Maryland Institute of Advanced Computer Science (UMIACS), University of Maryland, College Park, MD, USA asahu@jimmy.harvard.edu eyruppin@gmail.com.ORCID 0000-0002-7862-3940
Harvard University · USNational Institutes of Health · USUniversity of Maryland, College Park · USNew Jersey Institute of Technology · USThe Wistar Institute · USUniversity of California San Diego · USTel Aviv University · ILUniversity of California, Berkeley · USUniversity of Massachusetts Chan Medical School · US
Funding
Tumor Microenvironment and MetastasisP30CA010815 · NCI · WISTAR INSTITUTE · PI Luis J Montaner · 1985 to 2026
$75.9MTargeting the MAP and PI3 Kinase Pathways in MelanomaP01CA114046 · NCI · WISTAR INSTITUTE · PI MURPHY, MAUREEN E. · 2008 to 2023
$37.1MResearch Project 2 - Targeting Melanoma Tumor Survival and Apoptotic MachineryU54CA224070 · NCI · WISTAR INSTITUTE · PI Andrew V Kossenkov · 2017 to 2026
$13.9MTargeted Combination Therapy for MelanomaP50CA174523 · NCI · WISTAR INSTITUTE · PI HERLYN, MEENHARD F · 2014 to 2018
$11.1MTargeting the EGFR-PI3K/mTOR Signaling Circuitry: A Network-Based Approach for Oral Cancer Precision TherapyR01DE026870 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GUTKIND, JORGE SILVIO · 2018 to 2022
$2.3MPooled shRNA screens for target discoveries in cancerZIABC011438 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI LUO, JI · 2012 to 2021
$2.0MArea C: Genome-wide identification and targeting of resistance to cancer therapyR33CA225291 · NCI · UNIV OF MARYLAND, COLLEGE PARK · PI GUTKIND, JORGE SILVIO, RUPPIN, EYTAN · 2017 to 2017
$1.5MNCI NIH HHS P01 CA114046NCI NIH HHS P30 CA010815NCI NIH HHS P50 CA174523NCI NIH HHS R33 CA225291NCI NIH HHS U54 CA224070NIDCR NIH HHS R01 DE026870
Abstract
Most patients with advanced cancer eventually acquire resistance to targeted therapies, spurring extensive efforts to identify molecular events mediating therapy resistance. Many of these events involve
Indexed as
Computational BiologyDrug SynergismDrug Resistance, NeoplasmFemaleGene Expression ProfilingHumansImmunotherapyMaleMelanomaMolecular Targeted TherapySynthetic Lethal Mutationsdrug combinationdrug resistanceimmunotherapysynergy
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.